P53 Overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection

International Journal of Cancer

Volumn 97, Issue 4, 2002, Pages 451-457

  Liang, Jin Tung ^a   Huang, Kuo Chin ^a   Cheng, Yung Ming ^a   Hsu, Hey Chi ^a   Cheng, Ann Lii ^a   Hsu, Chih Hung ^a   Yeh, Kun Huei ^a   Wang, Shih Ming ^a   Chang, King Jen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

High dose 5 fluorouracil plus leucovorin chemotherapy (HDFL); p53 overexpression; Stage IV colorectal cancers

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; MUCIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOEMBRYONIC ANTIGEN; CELL DIFFERENTIATION; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENES, P53; HUMANS; LEUCOVORIN; LIFE TABLES; MUCINS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036466874     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1637     Document Type: Article

References (68)

1. p53: Guardian of the genome
2. p53: Puzzle and paradigm
3. Cancer cell cycle
4. p53, the cellular gatekeeper for growth and division
5. Roles for p53 in growth arrest and apoptosis: Putting the brakes after genotoxic stress
6. The p53 genes as a modifier of intrinsic radiosensitivity: Implications for radiotherapy
7. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
8. p53 status and the efficacy of cancer therapy in vivo
9. A genetic model for colorectal tumorigenesis
10. Tumor-suppressor p53: Implications for tumor development and prognosis
11. Clinical implications of p53 mutations
12. Cancer therapy and p53
13. The results of colorectal treatment by p53 status
14. The clinical significance of p53 aberrations in human tumors
15. American Joint Committee on Cancer Prognostic Factors Consensus Conference
16. Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: No evidence for prognostic significance
17. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer
18. Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer
19. Reappraisal of K-ras and p53 gene mutations in the recurrence of Dukes' B2 rectal cancer after curative resection
20. Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis
21. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas
22. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms
23. p53 alterations are associated with improved prognosis in distal colonic carcinomas
24. p53 in tumor pathology: Can we trust immunocytochemistry?
25. Comparative survival analysis of p53 gene mutations and protein accumulation in colorectal cancer
26. Impact of surgeon's technique on outcome after treatment of rectal carcinoma
27. Introduction: p53-the first twenty years
28. How to improve the present TNM staging system
29. Residual tumor (R) classification and prognosis
30. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in genetic and colorectal cancers
31. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas
32. Expression of favorable prognostic factor
33. p53 point mutation and survival in colorectal cancer patients
34. Association of p53 mutations with short survival in colorectal cancer
35. Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma
36. Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression
37. Prognostic value of p53 genetic changes in colorectal cancer
38. Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinama of the colon
39. Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer
40. Prognostic markers for colorectal cancer: Expression of p53 and BCL 2
41. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study
42. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: Impact survival of 388 patients with Dukes' C colon carcinoma
43. Prognostic factor research in oncology
44. Statistical aspects of prognostic factor studies in oncology
45. Issues in surgical randomized controlled trials
46. Response rates, survival and chemotherapy trials
47. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma
48. An alternative method to overcome central venous portable external infusion pump blockage in patients receiving weekly 24-hour high-dose fluorouracil and leucovorin
49. A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers
50. Toxicity and response criteria of the Eastern cooperative Oncology Group
51. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: Association with tumor growth and invasiveness
52. Molecular markers of prognosis in colorectal cancer
53. Genetic prognostic markers for colorectal cancer
54. An informationintensive approach to the molecular pharmacology of cancer
55. Anticancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development?
56. Adenoviral-mediated transfer of Escherichia coli uracil phophoribosyltransferase (UPRT) gene to modulate the sensitivity of the human colon cancer cells to 5-fluorouracil
57. p53 status and thymidylate synthetase (ts) expression are associated and predict for recurrence in patients with stage II colorectal cancer
58. p53 status and thymidylate synthetase in patients with advanced colorectal cancers
59. Molecular markers as prognostic factors to determine treatment
60. p53 and PCNA expression in advanced colorectal cancer: Response to chemotherapy and long-term prognosis
61. p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma
62. C-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-Fluorouracil in vitro and in vivo
63. Clinicopathologic and carcinogenetic appraisal of DNA replication error in sporadic T3NoMo stage colorectal cancer after curative resection
64. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer
65. Association of tumor site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer